| Literature DB >> 24758227 |
Xinyang Hu, Rongrong Wu, Lina A Shehadeh, Qing Zhou, Cizhong Jiang, Xin Huang, Ling Zhang, Feng Gao, Xianbao Liu, Hong Yu, Keith A Webster1, Jian'an Wang.
Abstract
BACKGROUND: The endosteum of the bone marrow provides a specialized hypoxic niche that may serve to preserve the integrity, pluripotency, longevity and stemness of resident mesenchymal stem cells (MSCs). To explore the molecular genetic consequences of such a niche we subjected human (h) MSCs to a pO2 of 4 mmHg and analyzed global gene expression and alternative splicing (AS) by genome-exon microarray and RT-qPCR, and phenotype by western blot and immunostaining.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24758227 PMCID: PMC4234502 DOI: 10.1186/1471-2164-15-303
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Characterization of hMSCs cultures under air or hypoxia. (A) Morphology and (B) surface antigen profiling of normoxic (N-MSC) and hypoxic hMSCs (H-MSC). Conditions and procedures are described in Methods. Representative of n = 3.
HIF-1 regulated transcripts
| Leptin | LEP | 74.3 |
| Insulin-like growth factor binding protein 1 | IGFBP1 | 8.93 |
| Phopshoglycerate kinase | PGK | 7.10* |
| Lysyl oxidase-like 4 | LOXL4 | 6.5 |
| Carbonic anhydrase IX | CA9 | 5.55 |
| Metallothionein 3 | MT3 | 4.78 |
| Vascular Endothelial Growth Factor A | VEGFA | 4.61 |
| Carbonic anhydrase XII | CA12 | 4.62 |
| Lysyl Oxidase | LOX | 3.99 |
| Basic helix-loop-helix family member 40 | BHLHE40 | 3.97 |
| Adrenomedullin | ADM | 3.39 |
| Placental Growth Factor | PGF | 3.28 |
| Phosphofructokinase | PFK | 3.20* |
| Insulin-like growth factor binding protein 3 | IGFBP3 | 3.10 |
| Angiopoietin-like 4 | ANGPTL4 | 2.88 |
| BCL2/adenovirus E1B 19 kDa interacting protein 3 | Bnip3 | 2.17 |
| Lactate Dehydrogenase-A | LDH-A | 2.10 |
| Glyceraldehyde-3-Phosphate Dehydrogenase | GAPDH | 1.48* |
| PhopshoGlycerate Mutase | PGAM | 0.70* |
| Solute carrier family 2 (facilitated glucose transporter), member 1 | SLC2A1 (GLUT 1) | 2.01 |
| Solute carrier family 2 (facilitated glucose transporter), member 3 | SLC2A1 (GLUT 3) | 2.11 |
Genes were identified from the gene expression array and all values are significant (p < 0.05, n = 3). For genes with (*), transcripts were quantified by QPCR using 3 different preparations of hMSCs run in duplicate; (PGK p < 0.001; PFK, p < 0.01; GAPDH, p = 0.21; PGAM, p = 0.02; all n = 7).
Figure 2Real-time PCR (RTqPCR) validation of differentially expressed genes. RTqPCR was implemented on the same mRNA samples used for microarray as described in Methods. Results are mean ± SEM of n = 3.
Figure 3Quantification of leptin and VEGF protein in MSC spent media during exposure to hypoxia. (A) Numbers in left panel refer to time (h) under hypoxia. (B) VEGF incubation time was 24 h. All results are representative of 3 separate experiments; *p < 0.05, n = 3.
Figure 4Heatmaps of differentially expressed genes in 2 main Gene Ontology (GO) molecular functions. Differentially expressed genes in human MSCs under hypoxia were subjected to GO analysis. A significance cut-off of p < 0.05 was used.
Up-regulated genes and functional group allocations
| | Leptin | LEP | 74.3 |
| Early Growth Response 2 | EGR2 | 6.78 | |
| Inhibin, beta B | INHBB | 6.25 | |
| Interleukin 11 | IL11 | 5.5 | |
| Growth differentiation factor 6 | GDF6 | 5.29 | |
| Hemopoietic cell kinase | HCK | 4.82 | |
| Podoplanin | PDPN | 3.65 | |
| Ephrin-A3 | EFNA3 | 3.65 | |
| Semaphorin A7 | SEMA7 | 2.70 | |
| Activin A receptor type IIA | ACVR2A | 2.70 | |
| Matrix metalloproteinase 11 | MMP11 | 2.52 | |
| Aggrecan | ACAN | 2.50 | |
| Sparc/osteonectin (testican) | SPOCK1 | 2.2 | |
| Frizzled homologue-8 | FZD8 | 3.2 | |
| Secreted frizzled related protein 4 | SFRP4 | 2.3 | |
| Cadherin 11, type 2 (osteoblast) | CDH11 | 2.0 | |
| | Transient receptor potential cation channel | TRPM7 | 6.63 |
| Interleukin 11 | IL11 | 5.5 | |
| Metallothionein 3 | MT3 | 4.80 | |
| Stanniocalcin 1 | STC1 | 4.8 | |
| Regucalcin | RGN | 4.04 | |
| Vascular endothelial growth factor A | VEGFA | 3.56 | |
| RAS p21 protein activator 1 | RASA1 | 2.92 | |
| Immediate Early Response 3 | IER3 | 2.52 | |
| | Insulin-like growth factor binding protein 1 | IGFBP1 | 8.93 |
| Insulin-like growth factor binding protein 3 | IGFBP3 | 3.1 | |
| Insulin-like growth factor binding protein 5 | IGFBP5 | 3.1 | |
| Interleukin 11 | IL11 | 5.5 | |
| Placental Growth Factor | PGF | 3.28 | |
| Transcription elongation factor A3 | TCEA3 | 2.82 | |
| Hepatocyte growth factor receptor | MET | 2.70 | |
| Heparin-binding EGF-like GF | HBEGF | 2.64 | |
| Jun B oncogene | JUNB | 3.07 | |
| c-Jun oncogene | JUN | 2.66 | |
| Inhibin, beta B | INHBB | 6.25 | |
| Growth differentiation factor 6 | GDF6 | 5.29 | |
| Inhibitor of growth family member 3 | ING3 | 3.53 | |
| | Early growth response 2 | EGR2 | 6.78 |
| Interleukin 11 | IL11 | 5.5 | |
| Activated leukocyte cell adhesion molecule | ALCAM | 2.89 | |
| Junctional adhesion molecule 2 | JAM2 | 3.10 | |
| Semaphorin 5A | SEMA5A | 4.02 | |
| Connective tissue growth factor | CTGF | 2.40 | |
| Protein tyrosine phosphatase, receptor type, F | PTPRF | 2.66 | |
| Signal-induced proliferation-associated 1 like 1 | SIPA1L1 | 4.0 | |
| Intergrins alpha- 1, 3, 5, 6, 7 | ITGA | >2.2 | |
| Integrin beta-1 | ITGB | 2.1 | |
| | Periplakin | PPL | 7.88 |
| Desmoplakin | DSP | 3.86 | |
| Keratin 16 | KRT16 | 6.39 | |
| Keratin 14 | KRT14 | 4.04 | |
| Keratin 20 | KRT20 | 4.40 | |
| Keratin 19 | KRT19 | 3.5 | |
| Keratin 15 | KRT15 | 3.35 | |
| Keratin 13 | KRT13 | 3.37 | |
| Keratin 24 | KRT24 | 3.09 | |
| Keratin 17 | KRT17 | 2.70 | |
| Keratin 12 | KRT12 | 2.60 | |
| Mucin 1 | MUC1 | 2.23 | |
| KIAA1199 | KIAA1199 | 5.2 | |
| RAS p21 protein activator | RASA1 | 2.92 | |
| Microtubule-associated protein 1B | MAO1B | 2.70 | |
| Microtubule-actin cross-linking factor 1 | MACF1 | 2.4 | |
| Lysyl oxidase-like 4 | LOX4 | 6.5 | |
| Lysyl oxidase-like 2 | LOX2 | 2.5 | |
| | Leptin | LEP | 74.3 |
| Stanniocalcin 1 | STC1 | 4.70 | |
| Vascular endothelial growth factor A | VEGFA | 4.61 | |
| Placental growth factor | PGF | 3.28 | |
| Hepatocyte growth factor receptor | MET | 2.70 | |
| PDGF receptor B | PDGFRB | 2.1 | |
| PDGF receptor A | PDGFRA | 2.0 | |
| Angiopoietin-like 4 | ANGPTL4 | 2.80 | |
| Serpin peptidase inhibitor member 1 | SERPINE1 | 4.92 | |
| Serpin peptidase inhibitor member 2 | SERPINE2 | 2.4 | |
| Tissue plasminogen activator | PLAT | 2.3 | |
| Endothelial tyrosine kinase, Ang 1 receptor | TEK | 5.16 | |
| Lysyl oxidase-like 4 | LOX4 | 6.5 | |
| Desmoplakin | DSP | 3.86 | |
| Noggin | NOG | 3.91 | |
| Glucose transporter member 1 | SLC2A1 | 2.01 | |
| Glucose transporter member 3 | SLC2A3 | 2.11 | |
| Glucose/fructose transporter member 5 | SLC2A5 | 2.0 | |
| Glucose transporter, member 14 | SLC2A14 | 2.88 | |
Genes were identified from the gene expression array using Genespring software and GO analysis to assign functional categories as described in Methods and manually from inspection of the arrays. All values are significant (p < 0.05, n = 3).
Down-regulated genes and functional group allocations
| | NAD(P)H dehydrogenase, Quinone 1 | NQO1 | −5.63 |
| Aldo-Keto Reductase 1C1 | AKR1C1 | −2.71 | |
| Aldo-Keto Reductase 1C2 | AKR1C2 | −2.61 | |
| Aldo-Keto Reductase 1C3 | AKR1C3 | −2.60 | |
| Aldo-Keto Reductase 1C4 | AKR1C4 | −4.28 | |
| Aldo-Keto Reductase1D1 | AKR1D1 | −3.04 | |
| Aldo-Keto Reductase 1B10 | AKR1B10 | −3.07 | |
| Aldo-Keto Reductase 1B15 | AKR1B15 | −2.10 | |
| Glucose 6 phosphate DH | G6PDH | −2.00 | |
| Thioredoxin reductase | TXNRD1 | −3.77 | |
| | Insulin-like growth factor 1 | IGF-1 | −3.2 |
| PI3-kinase regulatory subunit 2 | PIK3R2 | −2.9 | |
| Platelet derived growth factor receptor-like | PDGFRL | −2.85 | |
| Fibroblast growth factor 7 | FGF7 | −2.1 | |
| Cell cycle arrest checkpoint | RAD9B | −4.4 | |
| Mediator of DNA damage checkpoint 1 | MDC1 | −3.39 | |
| Helicase (DNA) B | HELB | −4.4 | |
| Inhibitor of DNA binding 1 | ID1 | −3.26 | |
| Inhibitor of DNA binding 2 | ID2 | −3.0 | |
| Inhibitor of DNA binding 4 | ID4 | −3.0 | |
| TNF superfamily, member 14 | TNFSF14 | −2.22 | |
| | Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 | PREX1 | −2.23 |
| Coronin 7 | CORO7 | −5.10 | |
| Formin homology 2 domain containing 1 | FHOD1 | −2.15 | |
| Actin filament associated protein 1 like 2 | AFPAP1L2 | −3.3 | |
| Palmdelphin | PALMD | −2.8 | |
| Tubulin, alpha 3D | TUBA3D | −3.9 | |
| | Glucose 6 phosphate DH | G6PDH | −2.00 |
| Pyruvate dehydrogenase (liver RBC) | PKLR | −2.61 | |
| Phosphoglycerate mutase 2 | PGAM2 | −3.00 | |
| Phosphoglycerate mutase 5 | PGAM5 | −2.27 | |
| Phosphogluconate dehydrogenase | PGD | −2.55 | |
| Glucose transporter, member 4 | SLC2A4 | −2.7 | |
| Glucose transporter, member 8 | SLC2A8 | −2.5 | |
| Glucose/fructose transporter, member 11 | SLC2A11 | −2.24 | |
| | Actin alpha-1 (Sk) | ACTA1 | −4.33 |
| Actin gamma-2 (SM) | ACTG2 | −5.83 | |
| Fer-1-like 5 (myotube formation) | FER1L5 | −5.30 | |
| Tripartite motif containing 16-like | TRIM16L | −4.95 | |
| Myosin heavy chain 2 | MYH2 | −4.0 | |
| Myosin heavy chain 7 | MYH7 | −3.0 | |
| Troponin T type 2 (cardiac) | TNNT2 | −2.8 | |
| ATPase calcium channel (cardiac) | ATP2A1 | −2.94 | |
| Myosin binding protein B (fast) | MYBPC2 | −2.79 | |
| Lysine acetyl transferase 2A | KAT2A | −3.45 | |
| Galactosidase beta-1-like (senescence) | GLB1L3 | −3.0 | |
| Eukaryotic translation initiating factor 2B subunit gamma 3 | EIF2B3 | −2.6 | |
| Eukaryotic translation elongating factor 1 epsilon 1 | EEF1E1 | −2.67 | |
| Osteocrin | OSTN | −2.3 | |
| Elongation factor RNA Pol II, 2 | ELL2 | −2.0 | |
| Telomerase associated protein-1 | TEP1 | −2.67 | |
| Death associated protein kinase 2 | DK2 | −2.4 | |
| Protein kinase C delta | PRKCD | −3.37 | |
| Interleukin-8 | IL8 | −3.05 | |
| Interleukin-19 | IL19 | −2.61 | |
| Interleukin-27 | IL27 | −3.30 | |
| Interleukin-28A | IL28A | −2.24 | |
| Chemokine (C-C motif) ligand 2 | CCL2 | −3.19 | |
Genes were identified from the gene expression array using Genespring software and GO analysis to assign functional categories as described in Methods; additional genes were identified manually from inspection of the arrays. All values are significant (p < 0.05, n = 3).
Figure 5Keratin induction and reorganization of intermediate- and micro-filaments under hypoxia. (A) Western blot of Keratin-16 expression in normoxic (N-MSC) and hypoxic (H-MSC) human MSCs. (B) Keratin immunostaining and (C) F-actin immunostaining of MSCs cultured for 24 h under normoxia (N-MSC) or hypoxia (H-MSC). Western blots and immunostaining are described in Methods. All results are representative of 3 separate experiments; *p < 0.05, n = 3.
Figure 6Western blot and quantification of phosphor-Akt expression in normoxic (N-MSC) and hypoxic (H-MSC) human MSCs (A and B). Western blot procedures are described in Methods. Akt-P-Thr308 quantification was by NIH image using total Akt as loading control; *p < 0.05, n = 3.
Figure 7Splicing maps of highly regulated genes with high splice indices. Genes were selected based on highest positive (LEP, IL11, IGFBP1, TEK, CA9, LOX4, HCK, ERG2) and negative (EFNA3, CORO7, FER1L5, MYH2, ACTA1) fold change of gene expression hypoxia vs. normoxia. Bar graphs indicate hypoxic/normoxic differential exonic expression levels (n = 3).
GO enrichment classification of alternatively spliced genes after hypoxia
| | | | | | |
| Induction of apoptosis by intracellular signals | SART1 | NM_005146 | 0.46 | Exon11 | Squamous cell carcinoma antigen recognized by T cells |
| Positive regulation of neuron apoptosis | PTPRF | NM_002840 | 2.56 | Exon34 | Protein tyrosine phosphatase, receptor type, F |
| Apoptosis | PPP1R13L | NM_006663 | 2.01 | Exon13 | Protein phosphatase 1, regulatory (inhibitor) subunit 13 like |
| | STEAP3 | NM_182915 | 2.22 | Exon6 | STEAP family member 3 |
| TNFRSF14 | NM_003820 | 2.39 | Exon8 | Tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) | |
| Negative regulation of apoptosis | ERCC2 | NM_001130867 | 0.42 | Exon8 | Excision repair cross-complementing rodent repair deficiency, complementation group 2 |
| Anti-apoptosis | SERPINB2 | NM_002575 | 0.48 | Exon8 | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 |
| | | | | | |
| Cell growth | ACTA1 | NM_001100 | 0.22 | Exon6 | Actin, alpha 1, skeletal muscle |
| NDRG4 | NM_001130487 | 2.62 | Exon5 | NDRG family member 4 | |
| Cell cycle checkpoint | ERCC2 | NM_001130867 | 0.42 | Exon8 | Excision repair cross-complementing rodent repair deficiency, complementation group 2 |
| Multicellular organism growth | ERCC2 | NM_001130867 | 0.42 | Exon8 | Excision repair cross-complementing rodent repair deficiency, complementation group 2 |
| Cell proliferation | ERCC2 | NM_001130867 | 0.42 | Exon8 | Excision repair cross-complementing rodent repair deficiency, complementation group 2 |
| MT3 | NM_005954 | 2.72 | Exon3 | Metallothionein 3 | |
| Cell cycle arrest | SART1 | NM_005146 | 0.46 | Exon11 | Squamous cell carcinoma antigen recognized by T cells |
| Positive regulation of cell proliferation | IL11 | NM_000641 | 7.99 | Exon5 | Interleukin 11 |
| Negative regulation of cell proliferation | PTPRF | NM_002840 | 2.56 | Exon34 | Protein tyrosine phosphatase, receptor type, F |
| | | | | | |
| Axon guidance | SLIT3 | NM_003062 | 0.44 | Exon1 | Slit homolog 3 (Drosophila) |
| SEMA5A | NM_003966 | 2.90 | Exon23 | Sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A | |
| Motor axon guidance | EGR2 | NM_000399 | 5.08 | Exon2 | Early growth response 2 |
| Cell migration | PVR | NM_001135770 | 0.49 | Exon3 | Poliovirus receptor |
| Positive regulation of cell migration | LAMB1 | NM_002291 | 0.46 | Exon9 | Laminin, beta 1 |
| Regulation of cell shape | ARAP1 | NM_001135190 | 0.45 | Exon5 | ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 |
| | | | | | |
| Positive regulation of angiogenesis | RUNX1 | NM_001122607 | 0.40 | Exon1 | Runt-related transcription factor 1 |
| Wound healing | SERPINB2 | NM_002575 | 0.48 | Exon8 | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 |
Differentially spliced genes in human MSCs under hypoxia, were subjected to GO analysis as described in Methods.
Figure 8Oxygen-dependent differential splicing of the ALDH3A2 and NDRG4 genes. (A) Expression of splice isoforms confirmed by RT-PCR of genes with prior evidence of AS. (B) Annotation of each alternative isoform (M2 and M1, top graphic), exon structure (middle graphic) and expression profiles (bottom graphic) for ALDH3A2. Light blue boxes indicate down-regulation for hypoxic (H) versus normoxic (N) MSCs; gray boxes indicate no significant change; white boxes indicate no probe detection above expression threshold. The green exon (exon10) indicates the unique exon of isoform M1. Exon expression values (log2) are displayed for both H-MSC (black data points) and N-MSC (red data points), ranked in order of genomic position on the x-axis. The various isoforms can be validated in the PCR result although there is no probe annotated to the isoform-specific exon. (C) Exon structure (top graphic) modified domain of AS (middle graphic) and expression profiles (bottom graphic) for NDRG4. Light red boxes indicate up-regulation for hypoxic (H) versus normoxic MSCs (N) MSCs; gray boxes indicate no significant change; white boxes indicate no probe detection above expression threshold. A Modified or disrupted conserved domain of differentially expressed exon is from the CDD database (NCBI). Exon expression values (log2) are displayed for both H-MSC (black data points) and N-MSC (red data points), ranked in order of genomic position on the x-axis.